Malignant neoplasm of breast
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We report a germline mutation of the PTEN (c.723dupT, exon 7) identified in a young woman with a simultaneous occurrence of breast cancer, dermatofibrosarcoma protuberans, and follicular neoplasm.
|
29510612 |
2019 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
The exact mechanism of ATO's carcinostatic effects in breast cancer is related to downregulating PTEN/AKT pathway via promoting RhoB.
|
31011573 |
2019 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
In the current experimental study, we scrutinized the chemoprotective effect of astraxanthin against the 7,12-dimethylbenz(a)anthracene (DMBA)-induced breast cancer via Nrf-2-Keap1 and NF-kB and mTOR/Maf-1/PTEN pathway.
|
31556759 |
2019 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
This study demonstrates that PUF60 is highly expressed in breast cancer; upregulation of PUF60 accelerates the progression of breast cancer through PTEN inhibition.
|
30697074 |
2019 |
Malignant neoplasm of breast
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
By contrast, silencing SALL2 induced downregulation of ERα and PTEN and activated the Akt/mTOR signaling, resulting in estrogen-independent growth and tamoxifen resistance in ERα-positive breast cancer.
|
31657150 |
2019 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
Also, primary breast cancer specimens, all ER positive and HER2 negative, were immunohistochemically investigated for phospho-S6 (pS6) and PTEN, to evaluate the mTOR and PIK3CA/Akt pathways.
|
29520681 |
2018 |
Malignant neoplasm of breast
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Various stimuli can increase pAKT levels and elevated basal pAKT levels are a feature of PTEN-deficient breast cancer cell lines.
|
29438745 |
2018 |
Malignant neoplasm of breast
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Cellular levels of p-AKT(Ser473/Thr308) and p-ERK1/2(Thr202/Tyr204), activating mutations of PIK3CA and inactivating mutations of PTEN may predict response to everolimus in breast cancer cells; these findings have potential applications for treatment personalization of everolimus in breast cancer patients.
|
29476223 |
2018 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
However, the synthetically lethal interaction between PTEN and ATM in breast cancer has not been reported.
|
29522753 |
2018 |
Malignant neoplasm of breast
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, high Notch-1 and low PTEN mRNA expression may predict poorer overall survival in women with breast cancer.
|
29743588 |
2018 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
Six genes showed PTEN-SSL patterns of activity in a large proportion of PTEN-deficient breast cancer cell lines and are potential specific vulnerabilities in PTEN-deficient breast cancer.
|
29566768 |
2018 |
Malignant neoplasm of breast
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Some of the tagging single-nucleotide polymorphisms of 5 genes ( PALB2, TP53, Nijmegen breakage syndrome 1, PTEN, and BRCA1-interacting protein 1) involved in the monoubiquitinated FANCD2-DNA damage repair pathway were significantly associated with breast cancer risk.
|
30799775 |
2018 |
Malignant neoplasm of breast
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we investigated the effects of 15d-PGJ<sub>2</sub> on the activity of PTEN, the inhibitor of the phosphoinositide 3-kinase (PI3K)-Akt axis, in human breast cancer (MCF-7) cells.
|
29550515 |
2018 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings suggest that functional interaction between Plac1 and Furin enhances breast cancer invasion and metastasis and the Furin/NICD/PTEN axis may act as an important therapeutic target for breast cancer treatment.
|
29704427 |
2018 |
Malignant neoplasm of breast
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Since TQ has been reported to up-regulate several growth factors such as vascular endothelial growth factor (VEGF), EGF and PTEN expression, the present review article discusses the targeting potential of TQ for therapeutic intervention against such types of breast cancer.
|
28606050 |
2018 |
Malignant neoplasm of breast
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
In this study, we perform a comprehensive analysis to investigate the effect of PTEN and SHIP gene expression on regulating lymph node metastasis in breast cancer.
|
30539826 |
2018 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
BMI1 and PTEN are key determinants of breast cancer therapy: A plausible therapeutic target in breast cancer.
|
30096458 |
2018 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
In summary, we establish and characterize a non-canonical PTEN-microRNA-MALAT1 axis that regulates tumorigenesis and describe for the first time that the MALAT1 lncRNA possesses novel tumor suppressive properties in colon and breast cancers.
|
29574704 |
2018 |
Malignant neoplasm of breast
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We demonstrate the utilities of iTextMine with two use cases involving the gene PTEN and breast cancer and the gene SATB1.
|
30576489 |
2018 |
Malignant neoplasm of breast
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
The significance of PTEN mutations resulting in variable PTEN expression and their impact on prognosis of breast cancer is not well established.
|
29653745 |
2018 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
The over-expression of certain receptors (ER, PgR, HER-2, VEGF-R), as well as alteration of several intracellular signal transduction pathways (the PI3K-AKT-mTOR pathway, MEK-MAPK pathway, loss of PTEN, etc ...) has a great impact on the likelihood of recurrence and progression of the disease, influencing the natural history of breast cancer.
|
28183251 |
2018 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
miR-19 targeting of PTEN mediates butyl benzyl phthalate-induced proliferation in both ER(+) and ER(-) breast cancer cells.
|
29864457 |
2018 |
Malignant neoplasm of breast
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
|
29110152 |
2018 |
Malignant neoplasm of breast
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, HOTAIR could bind specifically to EZH2 and PTEN, highlighting the capability of HOTAIR to inhibit the expression of PTEN by recruiting EZH2 in breast cancer, while the TCGA database demonstrated the expressions of PTEN were lower in breast cancer cells.
|
30048163 |
2018 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
|
29567542 |
2018 |